All In MedTech

Device Trial Radar · NCT03505567

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100

Pilot Comparative Study of the Kowa OCT Bi-μ and the Optovue iVue 100

Last checked: Nov 19, 2026Latest source record: Sep 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Apr 21, 2018

Primary completion

Sep 1, 2018

Study completion Sep 1, 2018

Sponsor

Lead sponsor
Kowa Research Institute, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Apr 23, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a prospective comparative study to gather pilot agreement and precision data in normal subjects, subjects with glaucoma, and subjects with retinal disease.

Conditions

  • Glaucoma
  • Retinal Disease
  • Healthy

Interventions

  • KOWA OCT Bi-µDevice

    Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.

  • Optovue iVue 100Device

    U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare KOWA OCT Bi-μ and Optovue iVue 100Time frame: 1-2 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Andover Eye Associates

    Andover, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.